loading
Iteos Therapeutics Inc stock is traded at $8.57, with a volume of 461.21K. It is down -1.38% in the last 24 hours and up +19.86% over the past month. ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
See More
Previous Close:
$8.69
Open:
$8.57
24h Volume:
461.21K
Relative Volume:
0.56
Market Cap:
$327.97M
Revenue:
$127.70M
Net Income/Loss:
$-121.25M
P/E Ratio:
-2.7206
EPS:
-3.15
Net Cash Flow:
$-120.32M
1W Performance:
+9.73%
1M Performance:
+19.86%
6M Performance:
+3.00%
1Y Performance:
-51.14%
1-Day Range:
Value
$8.45
$8.87
1-Week Range:
Value
$8.055
$8.87
52-Week Range:
Value
$4.80
$18.13

Iteos Therapeutics Inc Stock (ITOS) Company Profile

Name
Name
Iteos Therapeutics Inc
Name
Phone
857-204-4583
Name
Address
321 ARSENAL STREET, WATERTOWN
Name
Employee
173
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
ITOS's Discussions on Twitter

Compare ITOS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ITOS
Iteos Therapeutics Inc
8.57 305.04M 127.70M -121.25M -120.32M -3.15
Biotechnology icon
ONC
Beigene Ltd Adr
240.58 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
435.40 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.335 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
588.45 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
74.81 5.92B 0 -153.72M -103.81M -2.00

Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades

Date Action Analyst Rating Change
May-14-25 Downgrade H.C. Wainwright Buy → Neutral
May-14-25 Downgrade Leerink Partners Outperform → Market Perform
May-13-25 Downgrade JP Morgan Overweight → Neutral
Aug-13-24 Initiated Wells Fargo Overweight
May-05-21 Initiated H.C. Wainwright Buy
Oct-08-20 Initiated Robert W. Baird Outperform
Aug-18-20 Initiated JP Morgan Overweight
Aug-18-20 Initiated Piper Sandler Overweight
Aug-18-20 Initiated SVB Leerink Outperform
Aug-18-20 Initiated Wedbush Outperform
View All

Iteos Therapeutics Inc Stock (ITOS) Latest News

pulisher
10:04 AM

(ITOS) Trading Advice - news.stocktradersdaily.com

10:04 AM
pulisher
May 19, 2025

Balyasny Asset Management L.P. Buys Shares of 28,350 iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World

May 19, 2025
pulisher
May 19, 2025

Q2 Earnings Forecast for ITOS Issued By Leerink Partnrs - Defense World

May 19, 2025
pulisher
May 18, 2025

Q4 Earnings Forecast for ITOS Issued By Leerink Partnrs - Defense World

May 18, 2025
pulisher
May 18, 2025

The week in pharma: action, reaction and insight – week to May 16 - The Pharma Letter

May 18, 2025
pulisher
May 18, 2025

Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet - MSN

May 18, 2025
pulisher
May 17, 2025

Research Analysts Issue Forecasts for ITOS Q2 Earnings - Defense World

May 17, 2025
pulisher
May 17, 2025

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives $18.83 Average Target Price from Analysts - Defense World

May 17, 2025
pulisher
May 16, 2025

iTeos Therapeutics (NASDAQ:ITOS) Rating Lowered to “Hold” at Leerink Partnrs - Defense World

May 16, 2025
pulisher
May 16, 2025

Leerink Partners Reiterates “Market Perform” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World

May 16, 2025
pulisher
May 15, 2025

ITOS: ITeos Therapeutics Downgraded to Neutral by HC Wainwright & Co. | ITOS Stock News - GuruFocus

May 15, 2025
pulisher
May 14, 2025

iTeos Therapeutics: End To Belrestotug Program Leads To A Hold Rating (NASDAQ:ITOS) - Seeking Alpha

May 14, 2025
pulisher
May 14, 2025

Piper Sandler cuts iTeos stock price target to $12 from $16 - Investing.com Canada

May 14, 2025
pulisher
May 14, 2025

ITeos Therapeutics (ITOS) Sees Price Target Adjustment by Piper Sandler | ITOS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish - NewsBreak: Local News & Alerts

May 14, 2025
pulisher
May 14, 2025

ITeos Therapeutics (ITOS): Analyst Lowers Price Target, Rating R - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Strategic Shift and Strong Financials Position iTeos Therapeutics for Growth - TipRanks

May 14, 2025
pulisher
May 14, 2025

ITeos Therapeutics (ITOS) Downgraded by Leerink Partners | ITOS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

This Wayfair Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday - Benzinga

May 14, 2025
pulisher
May 14, 2025

Leerink Downgrades iTeos Therapeutics to Market Perform From Outperform - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

HC Wainwright Downgrades iTeos Therapeutics to Neutral From Buy - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

iTeos Therapeutics (ITOS) Receives Adjusted Price Target from We - GuruFocus

May 14, 2025
pulisher
May 14, 2025

iTeos Therapeutics (ITOS) Receives Adjusted Price Target from Wells Fargo | ITOS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

iTeos Therapeutics (ITOS) Faces Downgrade Following GSK's Decisi - GuruFocus

May 14, 2025
pulisher
May 14, 2025

GSK (GSK) and iTeos Halt Belrestotug Development After Disappoin - GuruFocus

May 14, 2025
pulisher
May 14, 2025

iTeos Therapeutics price target lowered to $12 from $16 at Piper Sandler - TipRanks

May 14, 2025
pulisher
May 14, 2025

iTeos Therapeutics (ITOS) Faces Downgrade Following GSK's Decision | ITOS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

GSK (GSK) and iTeos Halt Belrestotug Development After Disappointing Trial Results | GSK Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

iTeos Therapeutics (ITOS) Downgraded by Analyst with New Price T - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Leerink downgrades iTeos Therapeutics after termination of TIGIT program - TipRanks

May 14, 2025
pulisher
May 14, 2025

iTeos and GSK halt lung cancer drug development By Investing.com - Investing.com India

May 14, 2025
pulisher
May 14, 2025

GSK, partner iTeos end development programme for lung cancer drug belrestotug - Medical Dialogues

May 14, 2025
pulisher
May 14, 2025

ITeos Therapeutics (ITOS) Downgraded by JP Morgan | ITOS Stock N - GuruFocus

May 14, 2025
pulisher
May 13, 2025

As iTeos, GSK shelve belrestotug, prospects for TIGIT continue to dim - biocentury.com

May 13, 2025
pulisher
May 13, 2025

iTeos Therapeutics: TIGIT Falls, And A Zombie Rises? (NASDAQ:ITOS) - Seeking Alpha

May 13, 2025
pulisher
May 13, 2025

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop - insights.citeline.com

May 13, 2025
pulisher
May 13, 2025

JPMorgan cuts iTeos Therapeutics stock rating to neutral, target to $8 - Investing.com Australia

May 13, 2025
pulisher
May 13, 2025

GSK and iTeos end belrestotug antibody program By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

JPMorgan cuts iTeos Therapeutics stock rating to neutral, target to $8 By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

iTeos Therapeutics (ITOS) Downgraded by JPMorgan Analyst | ITOS Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

GSK, partner iTeos scrap development of lung cancer therapy - NewsBreak: Local News & Alerts

May 13, 2025
pulisher
May 13, 2025

iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash PileITeos Therapeutics (NASDAQ:ITOS) - Benzinga

May 13, 2025
pulisher
May 13, 2025

iTeos and GSK to drop belrestotug + dostarlimab collaboration - The Pharma Letter

May 13, 2025
pulisher
May 13, 2025

iTeos Reports Topline Interim Results from GALAXIES Lung-201 Stu - GuruFocus

May 13, 2025
pulisher
May 13, 2025

iTeos, GSK to shelve TIGIT drug after study setback - BioPharma Dive

May 13, 2025
pulisher
May 13, 2025

ITeos Terminates TIGIT Program After Phase 2 Lung Study Misses PFS Endpoint, Explores Options - Nasdaq

May 13, 2025
pulisher
May 13, 2025

ITeos, GSK discontinue lung cancer therapy development - KFGO

May 13, 2025
pulisher
May 13, 2025

Wedbush Adjusts Price Target on iTeos Therapeutics to $10 From $25, Maintains Outperform Rating - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

GSK (GSK) and iTeos Halt Development of Lung Cancer Drug Combo - GuruFocus

May 13, 2025
pulisher
May 13, 2025

GSK, iTeos Therapeutics End Belrestotug Development Program - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

iTeos stock rises despite clinical trial setback By Investing.com - Investing.com South Africa

May 13, 2025

Iteos Therapeutics Inc Stock (ITOS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.16
price down icon 17.27%
$31.18
price down icon 3.94%
$578.71
price down icon 0.54%
$286.89
price down icon 0.52%
$4.10
price down icon 2.24%
$72.94
price down icon 0.11%
Cap:     |  Volume (24h):